期刊文献+

Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine 被引量:18

Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine
原文传递
导出
摘要 Objective: To test the influence of homocysteine on the production and activation of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of matrix metalloproteinase-2 (TIMP-2) and on cell migration of cultured rat vascular smooth muscle cells (VSMCs). Also, to explore whether rosuvastatin can alter the abnormal secretion and activation of MMP-2 and TIMP-2 and migration of VSMCs induced by homocysteine. Methods: Rat VSMCs were incubated with different concentrations of homocysteine (50-5000 μmol/L). Western blotting and gelatin zymography were used to investigate the expressions and activities of MMP-2 and TIMP-2 in VSMCs in culture medium when induced with homocysteine for 24, 48, and 72 h. Transwell chambers were employed to test the migratory ability of VSMCs when incubated with homocysteine for 48 h. Different concentrations of rosuvastatin (10^-9-10^-5 mol/L) were added when VSMCs were induced with 1 000 pmol/L homocysteine. The expressions and activities of MMP-2 and TIMP-2 were examined after incubating for 24, 48, and 72 h, and the migration of VSMCs was also examined after incubating for 48 h. Results: Homocysteine (50-1000 μmol/L) increased the production and activation of MMP-2 and expression of TIMP-2 in a dose-dependent manner. However, when incubated with 5000 pmol/L homocysteine, the expression of MMP-2 was up-regulated, but its activity was down-regulated. Increased homocysteine-induced production and ac- tivation of MMP-2 were reduced by rosuvastatin in a dose-dependent manner whereas secretion of TIMP-2 was not significantly altered by rosuvastatin. Homocysteine (50-5000 μmol/L) stimulated the migration of VSMCs in a dose-dependent manner, but this effect was eliminated by rosuvastatin. Conclusions: Homocysteine (50-1000 μmol/L) significantly increased the production and activation of MMP-2, the expression of TIMP-2, and the migration of VSMCs in a dose-dependent manner. Additional extracellular rosuvastatin can decrease the excessive expression and acti- vation of MMP-2 and abnormal migration of VSMCs induced by homocysteine. Objective:To test the influence of homocysteine on the production and activation of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of matrix metalloproteinase-2 (TIMP-2) and on cell migration of cultured rat vascular smooth muscle cells (VSMCs). Also, to explore whether rosuvastatin can alter the abnormal secretion and activation of MMP-2 and TIMP-2 and migration of VSMCs induced by homocysteine. Methods:Rat VSMCs were incubated with different concentrations of homocysteine (50-5 000 μmol/L). Western blotting and gelatin zymography were used to investigate the expressions and activities of MMP-2 and TIMP-2 in VSMCs in culture medium when induced with homocysteine for 24, 48, and 72 h. Transwell chambers were employed to test the migratory ability of VSMCs when incubated with homocysteine for 48 h. Different concentrations of rosuvastatin (10-9-10-5 mol/L) were added when VSMCs were induced with 1 000 μmol/L homocysteine. The expressions and activities of MMP-2 and TIMP-2 were examined after incubating for 24, 48, and 72 h, and the migration of VSMCs was also examined after incubating for 48 h. Results:Homocysteine (50-1 000 μmol/L) increased the production and activation of MMP-2 and expression of TIMP-2 in a dose-dependent manner. However, when incubated with 5 000 μmol/L homocysteine, the expression of MMP-2 was up-regulated, but its activity was down-regulated. Increased homocysteine-induced production and activation of MMP-2 were reduced by rosuvastatin in a dose-dependent manner whereas secretion of TIMP-2 was not significantly altered by rosuvastatin. Homocysteine (50-5 000 μmol/L) stimulated the migration of VSMCs in a dose-dependent manner, but this effect was eliminated by rosuvastatin. Conclusions:Homocysteine (50-1 000 μmol/L) significantly increased the production and activation of MMP-2, the expression of TIMP-2, and the migration of VSMCs in a dose-dependent manner. Additional extracellular rosuvastatin can decrease the excessive expression and activation of MMP-2 and abnormal migration of VSMCs induced by homocysteine.
出处 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2013年第8期696-704,共9页 浙江大学学报(英文版)B辑(生物医学与生物技术)
基金 Project supported by the Health Ministry Scientific Research Fund of China (No. WKJ2011-2-018) the Zhejiang Provincial Natural Science Foundation of China (No. Y2100535) the Key Social Development Project of Zhejiang Province (No. 2010A23010) the Science and Technology Projects of Shaoxing (No. 2011A23011) the Science and Technology Plan Project of Zhejiang Province (No. 2012C33040) the Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents, China
作者简介 Corresponding authorE-mail: ghangyuan@hotmail.com
  • 相关文献

参考文献25

  • 1Amaboldi, L., Guzzetta, M., pazzucconi, F., Radaelli, G., Paoletti, R., Sirtori, c.R., Corsini, A., 2007. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol. Res., 56(6):503-508. [doi:10. 1 016/j.phr5.2007 .09.012].
  • 2Bescond, A., Augier, T., Chareyre, C., Garcon, D., Homebeck, W., Charpiot, P., 1999. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem. Biophys. Res. Commun., 263(2):498-503. [doi:10. 1006/bbrc.1999.1391].
  • 3Busti, C., Falcinelli, E., Momi, S., Grese1e, P., 2010. Matrix metalloproteinases and peripheral arterial disease. Intern. Emerg. Med., 5(1):13-25. [doi:10.1007/511739-009- 0283-y].
  • 4Castro, R., Rivera, I., Blom, H.J., Jakobs, c., Tavares, de Almeida, I., 2006. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J. Inherit. Metab. Dis., 29(1):3-20. [doi:1 0.1007/51 0545- 006-0106-5].
  • 5Cheng-Lai, A., 2003. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis., 5(1):72-78. [doi:10.1097/01.HDX.00000 50417.89309.F8].
  • 6Guo, H., Lee, J.D., Veda, T., Shan, J., Wang, J., 2003. Plasma homocysteine levels in patients with early coronary artery stenosis and high risk factors. Jpn. Heart J., 44(6): 865-871. [doi:10.1536/jhj.44.865].
  • 7Guo, H., Lee, J.D., Uzui, H., Yue, H., Wang, P., Toyoda, K., Geshi, T., Veda, T., 2007. Effects of heparin on the production of homocysteine-induced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells. Can. J. Cardiol., 23(4):275-280. [doi:10. 1016/S0828-282X(07)70754-7].
  • 8Guo, H., Liu, L., Shi, Y., Sun, A., Xu, F., Chi, J., Huang, D., 2010. Chinese yellow wine and red wine inhibit matrix metalloproteinase-2 and improve atherosclerotic plaque in LDL receptor knockout mice. Cardiovasc. Ther., 28(3): 161-168. [doi:10.1111/j.1755-5922.2009.00132.x].
  • 9Hagar, H.H., 2002. Folic acid and vitamin B\2 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol. Res.,46(3):2\3-219. [doi:10.1016/S1043-6618(02)00095-6].
  • 10Holven, K.B., Aukrust, P., Holm, T., Ose, L., Nenseter, M.S., 2002. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler. Thromb. Vasco Bioi., 22(4):699-703. [doi:1 0.1161/01.A TV.0000013288.35930.90].

同被引文献93

引证文献18

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部